Status:
RECRUITING
Transcatheter Arterial Infusion to Patients With Advanced Pancreatic Cancer
Lead Sponsor:
Fudan University
Conditions:
Pancreatic Cancer
Eligibility:
All Genders
18-80 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to evaluate the efficacy of gemcitabine and nab-paclitaxel venous injection plus transcatheter arterial infusion to Patients with Advanced Pancreatic Cancer.
Detailed Description
Pancreatic cancer is a highly lethal malignancy with a 5-year survival less than 10%. Approximately 80% of patients with pancreatic cancer are diagnosed at an advanced stage. Chemotherapy is one of th...
Eligibility Criteria
Inclusion
- Ability to understand and the willingness to sign a written informed consent document.
- Age ≥ 18 years and ≤ 80 years.
- Eastern Cooperative Oncology Group (ECOG) performance status 0-2.
- Histologically or cytologically confirmed advanced pancreas adenocarcinoma.
- Primary pancreatic cancer without major anti-cancer treatments.
- Locally advanced, or metastatic pancreatic cancer.
- Presence of at least of one measurable lesion in agreement to RECIST criteria.
- The expected survival ≥ 3 months.
- Adequate organ performance based on laboratory blood tests.
- Patients who are willing or able to comply with study procedures.
Exclusion
- Pregnant or nursing women.
- Patients who have received anti-tumor chemotherapy, radiotherapy, or other treatments.
- The diagnosis was confirmed by pathology as non-adenocarcinoma of pancreas.
- Inflammation of the digestive tract, including pancreatitis, cholecystitis, cholangitis, etc.
- Severe and uncontrollable accompanying diseases that may affect protocol compliance or interfere with the interpretation of results.
- Cardiovascular and cerebrovascular accidents.
- Allergic to study drugs.
- Other serious accompanying illnesses, which, in the researcher's opinion, could seriously adversely affect the safety of the treatment.
Key Trial Info
Start Date :
March 1 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 1 2028
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT06196788
Start Date
March 1 2024
End Date
January 1 2028
Last Update
March 21 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Shanghai Cancer Center
Shanghai, Shanghai Municipality, China, 200032